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We studied 2,259 German citizens after they returned
from dengue-endemic countries from 1996 to 2004.
Serotype-specific dengue antibodies indicated acute infec-
tions in 51 (4.7%) travelers with recent fever and 13 (1.1%)
travelers with no recent fever, depending largely on desti-
nation and epidemic activity in the countries visited.
T
he number of dengue cases reported worldwide and
the number of countries with endemic dengue activity
has increased dramatically in recent decades (1). The dis-
ease is endemic in most tropical parts of the world, many
of which are popular tourist destinations. Because of this
popularity, and probably also because of heightened
awareness, diagnoses of dengue in international travelers
have increased as well (2–4). 
Four dengue virus serotypes (DENV-1 to -4) are known
to cause a wide range of clinical features (5); these viruses
are transmitted mainly by Aedes aegypti mosquitoes. As in
indigenous populations, a large proportion of asympto-
matic infections are found in travelers (6,7). Recovery
from an infection provides lifelong immunity against that
serotype but confers only transient protection against het-
erologous infections (1), and sequential (secondary) infec-
tions may increase the risk of developing the more severe
manifestation, dengue hemorrhagic fever (DHF) (8). DHF
seems to occur rarely in European travelers, but several
cases have been reported (9).
Previous studies demonstrated that the risk of acquiring
dengue is highest when traveling in Southeast Asia (3,4,6).
In that region, the disease is most prevalent during and
after the rainy season, when vector breeding is maximal
(10).
Only in a few industrialized countries is imported
dengue fever a notifiable disease. In addition, substantial
underdiagnosis persists because the disease is not well
known to general practitioners in Western countries, and
adequate diagnostic tests are available only in specialized
clinics. Thus, little is known about dengue incidence in
travelers over time. As dengue transmission may vary not
only by season, but also from year to year, data derived
from short-term observations may overestimate or under-
estimate the risk for travelers. 
Determining the incidence of dengue in travelers is ham-
pered by the fact that dengue immunoglobulin (Ig) G anti-
bodies are broadly cross-reactive with other flaviviruses and
vaccines against them (e.g., yellow fever and Japanese
encephalitis). Previous studies to determine antibodies to
dengue viruses by using commercially available enzyme-
linked immunosorbent assay (ELISA) kits carry a risk for
overestimation because of this cross-reactivity. Recently
developed tests like the envelope/membrane (E/M) and
nonstructural protein NS1 serotype-specific IgM ELISAs
and NS1 serotype-specific IgG ELISA therefore offer new
opportunities for a more reliable diagnosis and for deter-
mining the infecting serotype (11,12).
The Study
To study the influence of increased worldwide dengue
activity on international travelers, 2,259 patients were
studied retrospectively for dengue antibodies after return-
ing from dengue-endemic countries. A 36-month period
from January 1996 to December 1998 was compared with
a 27-month period from January 2002 to March 2004. We
recruited travelers who came to the travel clinic of the
Berlin Institute of Tropical Medicine, Germany, with fever
(n = 1,091) or diarrhea without fever (n = 1,168) and for
whom serum samples were available. Thus, 2,259 patients’
serum samples were tested for anti-dengue IgM and IgG
by using an IgM-capture ELISA and an IgG indirect
ELISA (PanBio Pty Ltd., East Brisbane, Queensland,
Australia). A probable acute infection was defined accord-
ing to manufacturer’s instruction as having a sample:cali-
brator absorbance ratio of IgM >1.0. Acute probable
primary infection was characterized by the elevation of
IgM >1.0 with IgG <4.0, and acute secondary infection
was characterized by the elevation of IgG >4.0 (13). For a
more specific diagnosis, all serum samples from patients
with probable dengue infections were then investigated by
using E/M and nonstructural protein NS1 serotype-specif-
ic IgM ELISAs and NS1 serotype-specific IgG ELISA as
described previously (11,12). Furthermore, an additional
confirmatory testing was performed by using immunoflu-
orescence assays (Euroimmun AG, Luebeck, Germany),
and if these results were contrary, sera collected during the
acute phase of illness were processed by using polymerase
chain reaction assays to detect viral nucleic acid.
Among the recruited patients, 1,163 (51.5%) were
male. The median age was 33 years (range 2–79 years).
Antibodies were detected by the screening test in 127
(5.6%) serum samples, indicating probable acute dengue
infection. The more specific analysis confirmed infection
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patients with secondary immune response. One of these 8
secondary and none of the 56 primary infections led clini-
cally to DHF. Among 1,091 patients with fever and 1,168
diarrhea patients without fever, 51 (4.7%) and 13 (1.1%),
respectively, had an acute dengue infection. 
The highest prevalence of dengue antibodies (4.6%),
indicating acute infection, was found in patients returning
from Asia (n = 1,020) (Table 1), including Southeast Asia
(7.4% of 500 total travelers and 11% of 310 febrile travel-
ers) and the Indian subcontinent (1.8%). Traveling in
Southeast Asia was associated with a significantly higher
risk compared to other disease-endemic areas in Africa and
Latin America (odds ratio 5.3, 95% confidence interval
3.2–9.0). Comparing patients with and without acute
dengue infection, no significant difference was seen in the
median length of travel (28 vs. 24 days, respectively, p =
0.083, Mann-Whitney test) or the median age of the
patients (32 vs. 33 years, respectively, p = 0.58, Mann-
Whitney test). Patients 30–44 years of age had the highest
antibody prevalence (37 [3.8%] of 966).
When patients from 1996 to 1998 (n = 1,073) were
compared with those from 2002 to 2004 (n = 1,186), a
slight increase was seen in the overall prevalence, from
2.7% to 3.0%, although this finding was not significant (p
= 0.63). The Figure shows annual dengue prevalence
among travelers to Thailand and to the Indian subconti-
nent, highlighting that infection rates fluctuate strongly
between years and between quarters within years. In the
last quarter of 1997 and 1998, 64 travelers returned from
Thailand, and 14 (22%) acquired an acute dengue infec-
tion. Among those, 5 were infected by the serotype DENV-
1, 3 by DENV-2, and 4 by DENV-3 (Table 2). In 2 cases
the serotype was undetermined.
Conclusions
In this study population, 4.7% of all febrile patients
returning from different areas of the tropics had dengue
antibodies that indicated acute infection. This number
underlines the effect on international travelers to dengue-
endemic areas. As long as no dengue vaccine is commer-
cially available, the single-most effective preventive
measure is avoiding mosquito bites. This advice should be
included in every medical pretravel consultation. Among
patients without fever, 13 (1.1%) had detectable dengue
antibodies compatible with acute dengue infection, which
underscores that symptoms commonly associated with
dengue, such as fever, myalgia, arthralgia, and exanthema,
are helpful for diagnosis when present, but the absence of
typical symptoms does not exclude infection.
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Figure. Prevalence of anti-dengue antibodies in travelers accord-
ing to quarters of the year. Lines indicate acute dengue infection
after returning from Thailand (n = 223) or from the Indian subcon-
tinent (n = 495), both with and without fever, and in the total febrile
population returning from all travel destinations (n = 1,091). A study on 483 cases of imported dengue infections in
Europe showed that DHF developed in 2.7% of the
patients; immigrants from dengue-endemic countries
returning to Europe after visiting their home country were
at higher risk for more severe disease than Europeans (9).
The immunologic status of those patients was unknown.
However, immigrants from dengue-endemic countries
have a higher prevalence of dengue antibodies from previ-
ous infections. In our population, all 54 patients with pri-
mary dengue infection had classical dengue fever, and 1 of
8 patients with secondary dengue infection had DHF. The
patient with DHF was born in Sri Lanka and immigrated to
Germany 2 decades ago. These observations might be
taken as more evidence for the importance of letting
patients know that they have been infected with dengue
and should, therefore, protect themselves from infection
with subsequent serotypes.
Fluctuations in prevalence between years, especially
the maximal prevalence in 1998, correspond to similar
observations on record. In a study conducted among Israeli
travelers to Southeast Asia from 1994 to 1998, a sharp
increase in incidence was noted in 1998 compared with
previous years (14). Similar to the worldwide increase of
cases reported to the World Health Organization, the num-
ber of Swedish travelers returning from Southeast Asia
with dengue fever was considerably higher in 1998 than
during previous years (3). Decreasing resources for vector-
borne infectious disease prevention and control (15) might
have contributed to this epidemic in Southeast Asia, which
followed the economic crisis in 1997.
The risk among a cohort of Dutch short-term travelers
to dengue-endemic areas in Asia from 1991 to 1992
showed marked seasonal variation for the Indian subconti-
nent (7). In our population, such seasonal variations were
not detectable. The infection rates were more influenced
by major outbreaks, such as the one in India in 2003 or in
Southeast Asia in 1997 to 1998. Similar findings have been
described for Israeli travelers during their trip to Thailand
in 1998 (14) and in German travelers to Brazil and
Thailand in 2001 and 2002, respectively (4).
To screen our samples, ELISA-based tests for IgM and
IgG were combined. In a study performed with paired
serum samples, combining IgG and IgM ELISAs had a
sensitivity of 100% in primary infections and 99% in sec-
ondary infections. The specificity was 100% in non-fla-
vivirus infections and 80% in Japanese encephalitis virus
infections when an IgG sample:calibrator absorbance ratio
of 3.0 was used as a cutoff (13). However, because our
study was retrospective, only single serum samples were
available from each traveler. To increase specificity, all
serum samples that indicated probable infections were fur-
ther investigated with more specific ELISAtechniques. By
using virus-infected culture supernatants as the source of
viral antigens, the E/M-specific capture IgM has been
found to differentiate reliably between Japanese encephali-
tis, dengue, West Nile virus, and yellow fever (12).
Furthermore, an NS1 isotype- and serotype-specific
ELISA can reliably differentiate Japanese encephalitis
virus infection, Japanese encephalitis virus vaccination,
and primary and secondary dengue virus infection (11). In
primary infection, IgM is detectable 3–8 days from the
onset of symptoms (8); thus, some of our travelers might
have had false-negative test results if samples were taken
during the acute phase of illness. Therefore, the true infec-
tion rates in our study might have been higher than the
numbers indicated by single-sample serology.
Overall, we demonstrated an almost stable rate of
dengue infections among Berlin Institute of Tropical
Medicine patients returning from all tropical regions when
recent years are compared with the mid-1990s. Large out-
breaks like those in 1997–1998 in Southeast Asia (espe-
cially Thailand) and 2003 in major cities of India, all
popular tourist destinations, contributed to the numbers.
Quarterly and annual fluctuations might lead to misinter-
pretation of probable trends if data are derived only from
short-term observations. In addition, this variability under-
scores the importance of tourists’ seeking information
before traveling to dengue-endemic areas.
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